RESUMEN
The potential application of dendritic cells (DC) sensitized with cytosine-phosphoric acid-guanine (CpG) oligodeoxynucleotide (ODN) and tumor antigen as a vaccine against murine melanoma was investigated with freshly isolated mouse bone marrow-derived dendritic cells. For the DC vaccine preparation, DC were sensitized with the B16 tumor antigen and CpG ODN was used to promote further maturation of the DC. The immunogenic activity of the vaccine was evaluated in vitro by determining the proliferation of T lymphocytes and the killing effect of cytotoxic T lymphocytes (CTL) on B16 tumor cells. The DC vaccine was injected intraperitoneally and tumor inhibition in mice bearing B16 xenografts was examined. All mice were cared for under an approved SIMM Institutional Animal Care and Use Committee (IACUC) protocol. In vitro, this DC vaccine promoted the proliferation of T lymphocytes and showed a potent killing effect on the target B16 cells. In vivo experiments showed that after treatment or pre-immunization both the tumor volume and weight were significantly decreased. The DC vaccine with CpG ODN and tumor antigen exhibited an inhibitory effect against melanoma, providing a potential method for melanoma cancer treatment.
RESUMEN
More and more studies have shown that NOD-like receptor protein 3 (NLRP3) inflammasome has become the regulatory factor of inflammatory response and protective immunity, and the assembly and activation of NLRP3 inflammasomes are closely related to the anti-tumor immunity effect. Depending on the cell type and stimuli, activation of the NLRP3 inflammasome can induce immune cells to become polarized, hyperactive, or pyroptotic, releasing interleukin (IL)-1β and IL-18, which leads to cascade immune or inflammatory responses, and its role in tumor immunity has received extensive attention. Here, we review the mechanisms of the NLRP3 inflammasome enhancing CD8+ T cells-mediated anti-tumor immunity by inducing the pyroptosis of tumor cell, the pyroptosis or hyperactive state of dendritic cells (DCs), and the pyroptosis or polarization of the macrophages. Different anti-tumor immune roles of NLRP3 inflammasome activation in tumor cells and immune cells provide new directions for future research and may influence the development of next-generation immunotherapy.
RESUMEN
Dendritic cells (DCs) are the most powerful and professional antigen-presenting cells (APCs) known at present. They play vital roles in the initiation and regulation of immune responses in body. Therefore, DC-based vaccine delivery system has gradually become a hotspot of basic scientific research and clinical treatment. DCs can be loaded with whole-cell antigens, nucleic acids, peptides, proteins (such as neoantigens) and nanoparticles to induce specific cellular immune responses and humoral immune responses after antigen processing, presentation and targeting delivery in vivo for the prevention and treatment of various diseases including cancers and microorganism infections. Vaccine-based on this technique is called dendritic cell (DC) vaccines. Great process in DC vaccines has been achieved in recent years. Therefore, we reviewed the characteristics of DC, types of DC vaccines and their clinical research progress in this paper.
RESUMEN
Distinct from conventional cancer therapies focusing directly on local tumors, cancer immunotherapy aims to restore or enhance immune surveillance to fight against cancer, which bears the advantages of less side effects, lasting efficacy, substantial specificity and suitability for individualized treatment. As the most powerful antigen-presenting cell type, dendritic cells (DCs) can induce potent antigen-specific immune responses in vivo. DCs-based immunotherapy acts by loading DCs with cancer antigens in various ways to elicit specific anti-tumor immune responses. Currently, pulsing DCs with cancer antigen encoding mRNAs is an antigen loading approach under extensive study, registering encouraging results in relevant immunotherapeutic clinical trials. Thus, pulsing DCs with mRNAs is a new and highly promising modality in cancer immunotherapy.
RESUMEN
Immunotherapy is the most active research area for cancer treatment. Tumor vaccine is one of the most developed aspects of cancer immunotherapy. Though tumor vaccine has made many breakthrough, it still faces many challenges. In this study, we coated the black phosphorus quantum dots (BPQDs) with cancer cell membrane to create a nanoparticle named BPQD-CCNVs. The BPQD-CCNVs were incubated with bone marrow-derived dendritic cells and irradiated with 808 nm infrared light. We tested the expression level of CD80, CD86 and MHC II of dendritic cells by flow cytometry after irradiation. All animal experiments approved by the Animal Experiments Ethical Committee of Tsinghua University. The results showed that the rise of medium's temperature caused by the photothermal effect of BPQDs could upregulate the expression of CD80, CD86 and MHC-II on dendritic cell surface. Based on these, we conclude that near infrared irradiation can stimulate the activation of dendritic cells. Our study may have provided a new strategy for tumor vaccine development.